Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 16Squamous Cell Carcinoma of Head and Neck 11Esophageal Squamous Cell Carcinoma 11Esophageal Neoplasms 9Head and Neck Neoplasms 8Uterine Cervical Neoplasms 7Pancreatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Pancreatic cancer, adult 2Neoplasms 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Anal Canal 1Solid Tumors 1Solid Tumor 1Resectable Pancreatic Cancer 1Recurrence 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Diseases 1NSCLC 1Meningeal Carcinomatosis 1Locally Advanced Rectal Cancer 1

Interventions

nimotuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Esophageal × nimotuzumab × Clear all
NCT00950417 2015-08-19

Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer

Biotech Pharmaceutical Co., Ltd.

Phase 1 Completed
11 enrolled
Gastrointestinal

Advanced Esophageal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡